Blood cancers have seen tremendous advancements in the past few years due to the dedication of researchers pulling out all the stops to churn out therapeutic innovations intended to be of service to suffering patients. These experimentations and their upshots are always brought to us through various platforms, the American Society of Hematology (ASH 2021) being one of them. On this note, DelveInsight has listed down a few of the major abstracts, including some late breakers from the conference that might help patients as well oncologists choose the best amongst the rest.
Breakthrough results from Phase III POLARIX study in front-line DLBCL
Pivotal POLARIX study ...
